Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2013-08-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Two Liquid Oxygen Devices in Deambulation
NCT01086891
Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
NCT04089826
High Flow in Interstitial Lung Disease
NCT03816722
Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic
NCT01898858
Effect of Three Modalities of Spontaneous Breathing Tests on Respiratory Efforts in Tracheostomized Patients
NCT03856424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ambulatory oxygen is traditionally delivered via a refillable portable oxygen cylinder containing compressed gaseous oxygen. More recently, portable oxygen concentrators (POCs) have emerged as a solution to the problem of finite cylinder life and to improve portability. Because a concentrator is constantly extracting oxygen from air, oxygen supply can continue as long as the battery is charged. This is typically around eight hours, but POCs can be recharged from an AC or DC power source. Portable oxygen concentrators usually weigh around 3.5kg, which is significantly lighter than oxygen cylinders, and are much easier to maneuver. However, there are some theoretical disadvantages to POCs. Like all concentrators, they do not deliver 100% oxygen. Concentrations typically range from 85-95%, depending on the flow rate. Differences in pulse timing and peak pulse flow between POCs may affect the fraction of inspired oxygen (FiO2) that is delivered. However, the clinical implications of these differences have not been documented.
The aim of this study is to compare the effects of ambulatory oxygen delivered during exercise using the EverGo POC to ambulatory oxygen delivered with a standard portable cylinder in individuals with ILD. We hypothesise that oxyhaemoglobin saturation during exercise will be significantly higher when using a portable cylinder, but this difference will not be clinically important.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Portable Oxygen Concentrator first
Portable oxygen concentrator
Respironics EverGo portable oxygen concentrator on setting 6
Portable oxygen cylinder
Portable oxygen cylinder at flow rate 5 Litres/min
Portable oxygen cylinder first
Portable oxygen concentrator
Respironics EverGo portable oxygen concentrator on setting 6
Portable oxygen cylinder
Portable oxygen cylinder at flow rate 5 Litres/min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Portable oxygen concentrator
Respironics EverGo portable oxygen concentrator on setting 6
Portable oxygen cylinder
Portable oxygen cylinder at flow rate 5 Litres/min
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* desaturate to less than 90% during a 6-minute walk test
Exclusion Criteria
* currently using continuous oxygen therapy
* oxyhaemoglobin saturation (SpO2) is less than 90% on room air
* unable to perform a 6-minute walk test or comorbidities that limit walking
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Alfred
OTHER
Anne Holland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Holland
Clinical Chair, Physiotherapy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alfred Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
187_13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.